Christopher Cannon/LinkedIn
Feb 16, 2026, 13:21
Christopher Cannon: Factor XIa Inhibition Reduces Stroke Risk in Non-Cardioembolic Stroke and High-Risk TIA
Christopher Cannon, Cardiologist at Brigham and Women’s Hospital, Editor-in-Chief of Harvard Heart Letter, shared a post on LinkedIn:
”Factor XIa inhibition works! When added to antiplatelet therapy for non-cardioembolic ischemic stroke or high-risk TIA, XIa inhibition significantly reduced stroke by 26%, with no significant increase in bleeding!”
Title: Next-Generation Factor XIa Cuts Recurrent Stroke Risk by 26%— Asundexian prevented repeat strokes without bleeding side effects
Authors: Nicole Lou
Read the Full Article on MedPage Today։
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 2, 2026, 14:30Sadashiva Pai: The Molecular Gateway for Sphingosine-1-Phosphate Release
-
Oct 2, 2026, 14:17Aditya Rawat: Clopidogrel, CYP2C19 and the Role of Pharmacogenetics
-
Oct 2, 2026, 14:12Monitoring Iron Deficiency in Glanzmann Thrombasthenia – Glanzmann’s Research Foundation
-
Oct 2, 2026, 14:06Giang Tran: Residual Internal Carotid Artery Aneurysm After Flow-Diverter Stenting
-
Oct 2, 2026, 14:05Shadiah Nassanga: The Economic Impact of Sickle Cell Disease
-
Oct 2, 2026, 13:56Mapping the Care Gaps for Hemophilia and Sickle Cell Disease in Ghana – Novo Nordisk Haemophilia and Haemoglobinopathies Foundation
-
Oct 2, 2026, 13:50Arnav Garcha: New Insights Into Platelet Transport in Arterial Flow
-
Oct 2, 2026, 13:49Alessandro Lucchesi: RiseMPN 2026 – Shaping the Future of MPN Treatment
-
Oct 2, 2026, 13:43Ronald Mahomane: Bangladesh Moves Toward Sustainable Hemophilia Treatment Access